Form 4: Tandem Diabetes CEO Increases Stake via RSU Vesting

Tandem Diabetes Care Inc. CEO John F. Sheridan reported the vesting and exercise of restricted stock units, resulting in a net increase in his direct beneficial ownership of common stock.

Summary

• John F. Sheridan, President & CEO and Director of Tandem Diabetes Care Inc. (TNDM), reported transactions related to his beneficial ownership of common stock.
• On November 17, 2025, Mr. Sheridan acquired 5,472 shares of common stock through the vesting of Restricted Stock Units (RSUs) at a price of $0.
• Concurrently, 2,779 shares were disposed of at $18.61 to satisfy tax withholding requirements related to the RSU vesting.
• Additionally, on November 17, 2025, Mr. Sheridan acquired another 5,982 shares of common stock through the vesting of RSUs at a price of $0.
• Another 3,038 shares were disposed of at $18.61 to satisfy tax withholding requirements for this second RSU vesting.
• The shares withheld for tax were not a sale but a standard procedure by Tandem Diabetes Care Inc. to cover tax liabilities.
• Following these transactions, Mr. Sheridan's direct beneficial ownership of common stock stands at 117,600 shares.
• The transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the transactions are routine compensation events, the net increase in the CEO's beneficial ownership is generally viewed favorably as it aligns management's interests with shareholders. There are no negative discretionary actions.

Positives

• The CEO's beneficial ownership of common stock increased by a net of 5,637 shares (11,454 acquired 5,817 disposed for tax), which can be viewed as a positive signal of management's continued alignment with shareholder interests.
• The transactions are part of a pre-established plan (Rule 10b5-1(c)), indicating routine compensation events rather than discretionary sales.

Negatives

• A portion of shares (5,817) were withheld to cover tax obligations, which is a standard practice for RSU vesting and not indicative of a negative outlook.

Future Outlook

The remaining shares from the May 25, 2023 RSU award will vest in eight equal quarterly installments after May 15, 2024. The remaining shares from the May 23, 2024 RSU award will vest in eight equal quarterly installments after May 15, 2025.

Industry Context

This filing represents a routine insider transaction related to executive compensation, common across publicly traded companies, particularly for executives receiving Restricted Stock Units as part of their long-term incentive plans. It does not provide specific insights into broader industry trends or competitive landscape beyond the company's internal compensation practices.

Stakeholder Impact

• Shareholders: May view the net increase in CEO ownership as a positive signal of management's commitment and confidence in the company's future performance.
• Employees: No direct impact mentioned, but RSU vesting is a common form of equity compensation.

Next Steps

• Future vesting of remaining Restricted Stock Units according to the established schedules (eight equal quarterly installments after May 15, 2024, for the 2023 award, and after May 15, 2025, for the 2024 award).

Key Dates

Recommendation

This Form 4 reports routine RSU vesting and tax withholding for the CEO. While the net increase in beneficial ownership is a positive signal of insider confidence, it does not represent a discretionary open market purchase or sale that would typically warrant a change in investment recommendation. The transactions are part of a pre-established compensation plan and do not alter the fundamental outlook or valuation of the company.

Keywords

Tandem Diabetes Care, TNDM, Form 4, Insider Transaction, Restricted Stock Units, RSU, CEO Stock, Beneficial Ownership, John F. Sheridan, Executive Compensation